Working… Menu

A Dose-finding Study of OPC-41061 in Treatment of Cardiac Edema (Congestive Heart Failure)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00234104
Recruitment Status : Completed
First Posted : October 6, 2005
Results First Posted : December 25, 2013
Last Update Posted : December 25, 2013
Information provided by (Responsible Party):
Otsuka Pharmaceutical Co., Ltd.

Brief Summary:
This drug is being developed to treat cardiac edema. The primary purpose of this study is to investigate the dose response for body weight in seven-day repeated oral administration of OPC-41061 at 15, 30, and 45 mg or placebo in patients with extracellular volume expansion secondary to CHF despite taking furosemide at 40 mg/d or more. This study is being conducted in Japan.

Condition or disease Intervention/treatment Phase
Heart Failure, Congestive Edema Drug: OPC-41061(Tolvaptan) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 122 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of OPC-41061 in Congestive Heart Failure Patients With Extracellular Volume Expansion
Study Start Date : August 2004
Actual Primary Completion Date : January 2006
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Tolvaptan

Primary Outcome Measures :
  1. Body Weight [ Time Frame: Baseline, at the time of final trial drug administration ]
    The body weight change from baseline following final trial drug administration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with CHF who exhibit edema, jugular venous distention, hepatomegaly, pulmonary congestion, or 3rd sound due to extracellular volume expansion
  2. Hospitalized patients or patients who can be hospitalized for the study from the commencement of the observation period to the end-of-study examination
  3. Men and women between the ages of 20 and 80 (non-inclusive) at the time of giving consent
  4. Patients who have taken furosemide at 40 mg/d or more (oral dosing) without alteration of dosage for the 3 days of the observation period
  5. Patients whose body weight has been stable (±1.0 kg) for 2 days prior to commencement of study drug administration

Exclusion Criteria:

  1. Patients with unstable heart failure (acute heart failure, acute exacerbation of chronic heart failure, etc)
  2. Patients with an implanted ventricular assist device
  3. Patients who have undergone or are scheduled to undergo any of the following procedures

    • Heart surgery involving thoracotomy within 60 days prior to the screening examination
    • Pacemaker implant surgery involving bilateral pacing within 60 days prior to the screening examination
    • Angioplasty, electrophysiologic device implantation, ventricular assist device implantation, heart transplant, or other cardiac surgery scheduled within 30 days after the screening examination
  4. Patients with any of the following diseases, complications, or symptoms

    • Suspected hypovolemia
    • Onset of acute myocardial infarction within 30 days prior to the screening examination
    • Hypertrophic cardiomyopathy (excluding diastolic phase)
    • Definitively diagnosed active myocarditis or amyloid cardiomyopathy
    • Valvular heart disease with significant stenosis
    • Untreated thyroid disease
    • Progressive neurological disease (Alzheimer's disease, Parkinson's disease, multiple sclerosis, etc) or severe episodic neurological disease (epilepsy, Guillain-Barre syndrome, etc)
    • Diabetes with poor glycemic control
    • Anuria
    • Hepatic coma
    • Hyponatremia of moderate or greater severity (serum Na < 120 mEq/L)
  5. Patients with a history of the following conditions

    • Occurrence of sustained ventricular tachycardia or ventricular fibrillation within 30 days prior to the screening examination (except for patients using an implantable cardioverter-defibrillator)
    • Evident cerebral infarction
    • Multiple stroke
    • Occurrence of a cerebrovascular accident within 30 days prior to the screening examination
    • Hypersensitivity or idiosyncratic reaction to benzazepine derivatives, such as benazapril
  6. Patients with a history of drug abuse or alcoholism in the past year
  7. Patients in a state of morbid obesity with a body mass index (weight[kg] ÷ height [m]2) over 35
  8. Patients with a supine systolic arterial blood pressure of less than 90 mmHg
  9. Patients with any of the following abnormal laboratory values: Hemoglobin <9 g/dL, total bilirubin >3.0 mg/dL, serum creatine >3.0 mg/dL, serum Na >147 mEq/L, or serum K >5.5 mEq/L
  10. Patients not capable of taking oral medication
  11. Patients who are nursing, pregnant, capable of pregnancy, or intending to become pregnant during or shortly after the study period
  12. Patients who have taken a study drug other than OPC-41061 within 30 days prior to screening
  13. Patients who have previously taken OPC-41061 in this study or another study of OPC-41061
  14. Patients otherwise judged by the principal investigator or attending investigator to be inappropriate for inclusion in the study (eg, patients with hepatic cirrhosis, renal disease, etc.)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00234104

Layout table for location information
Otsuka Pharmaceutical Co., Ltd.
Tokyo, Japan
Sponsors and Collaborators
Otsuka Pharmaceutical Co., Ltd.
Layout table for investigator information
Study Director: Katsuhisa Saito Division of New Product Evaluation and Development

Layout table for additonal information
Responsible Party: Otsuka Pharmaceutical Co., Ltd. Identifier: NCT00234104     History of Changes
Other Study ID Numbers: 156-03-001
First Posted: October 6, 2005    Key Record Dates
Results First Posted: December 25, 2013
Last Update Posted: December 25, 2013
Last Verified: November 2013
Keywords provided by Otsuka Pharmaceutical Co., Ltd.:
Heart Failure
Extracellular volume expansion
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases
Signs and Symptoms
Antidiuretic Hormone Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Physiological Effects of Drugs